DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for hypertrophic cardiomyopathy 10 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypertrophic cardiomyopathy 10 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypertrophic cardiomyopathy 10 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
myosin light chain 2 (MYL2) — MYL2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9TPJ · 3.02 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Hypertrophic cardiomyopathy has been recognised since the late 1950s, and by 1987 investigators had assembled observations on its clinical identification, morphology, pathophysiology, and natural history, though intrinsic complexities continued to create uncertainty and debate. A 1986 review of the pathology of the disease was published in the Postgraduate Medical Journal. A 2001 article summarised hypertrophic cardiomyopathy as a familial cardiac disorder with heterogeneous expression and a diversity of morphological, functional and clinical features; some individuals may be asymptomatic while others are disabled by angina and breathlessness. A 2019 review stated that surgical treatment is still the method of choice for hypertrophic cardiomyopathy and can guarantee excellent immediate and long-term results with minimal risk.
A 2006 case report described a patient who developed dilative cardiomyopathy after 16 years of treatment with lithium carbonate. The authors noted good evidence for acute cardiac reactions, especially cardiac arrhythmia, but a rather speculative association with long-term reactions such as cardiomyopathy. They advised that clinicians should be aware of this rare but life-threatening conjunction of cardiac disease and lithium treatment. No other drugs are mentioned in these abstracts.
No controlled trial data, no response rates, and no survival numbers are reported in any of these abstracts. The evidence consists of narrative reviews and a single case report linking lithium to a different form of cardiomyopathy. What is still missing is any randomised trial of a drug for hypertrophic cardiomyopathy, any patient stratification by genotype or phenotype, and the funding to conduct such studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1987 · 900 citations
Hypertrophic Cardiomyopathy
Abstract(First of Two Parts)HYPERTROPHIC cardiomyopathy has fascinated and often confused physicians for the quarter of a century since its recognition in the late 1950s.1 2 3 4 5 During this time, investigators have assembled an impressive array of observations spanning numerous aspects of the clinical identification, morphology, pathophysiology, and natural history of the disease. Much understanding has emerged from these investigative efforts; however, the intrinsic complexities of hypertrophic cardiomyopathy continue to create uncertainty and debate.Numerous studies have explored specific facets of hypertrophic cardiomyopathy, and several have comprehensively reviewed the broader aspects of its clinical profile and course, including the findings on physical . . .
Postgraduate Medical Journal · 1986 · 175 citations · open access
Pathology of hypertrophic cardiomyopathy
AbstractJournal Article Pathology of hypertrophic cardiomyopathy Get access E G J Olsen E G J Olsen National Heart Hospital, London W1M 8BA, U.K. Correspondence: E.G.J. Olsen, M.D., F.R.C.Path., F.A.C.C. Search for other works by this author on: Oxford Academic Google Scholar Postgraduate Medical Journal, Volume 62, Issue 728, June 1986, Pages 575–576, https://doi.org/10.1136/pgmj.62.728.575 Published: 01 June 1986
Journal of Psychopharmacology · 2006 · 20 citations
Cardiomyopathy after long-term treatment with lithium – more than a coincidence?
AbstractWe describe a patient suffering from dilative cardiomyopathy after 16 years of treatment with lithium carbonate. The literature concerning lithium and cardiac adverse reactions is briefly reviewed. There is good evidence for acute cardiac reactions, especially cardiac arrhythmia but a rather speculative association with long-term reactions such as cardiomyopathy. Nevertheless clinicians should be aware of this rare but life threatening conjunction of cardiac disease and lithium treatment.
Pirogov Russian Journal of Surgery · 2019 · 10 citations · open access
Hypertrophic cardiomyopathy: current state of the problem
AbstractThe main aspects of epidemiology, pathophysiology, medication and surgical treatment of hypertrophic cardiomyopathy (HCM) are reviewed in the article. The authors emphasize that surgical treatment is still the method of choice for HCM and can guarantee excellent immediate and long-term results with minimal risk.
AbstractHypertrophic cardiomyopathy is a familial cardiac disorder with heterogeneous expression and a diversity of morphological, functional and clinical features. Some individuals with hypertrophic cardiomyopathy may be asymptomatic while others are disabled by symptoms of angina and breathlessness. This article summarizes the genetics, pathophysiology and present management of this important condition.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
